Download scoring documents for this measure. BACK FACT-Ga Scoring Downloads Download DOC

Download scoring documents for this measure. BACK FACT-RNT Scoring Downloads Download DOC

Download scoring documents for this measure. BACK FACIT-Dyspnea Item Bank Scoring Downloads Not Available

View all available languages for this measure. BACK HAMSIQ Languages English Finnish French German Italian Swedish

Download this measure in English. BACK FACT-GP English Downloads Download PDF Download DOC

Download scoring documents for this measure. BACK FACT-Th18 Scoring Downloads Download DOC

FACIT-SWiP Functional Assessment of Chronic Illness Therapy - Satisfaction with Pharmacist Satisfaction with Pharmacist Scale LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview Below are the details for the FACIT-SWiP measure: MEASURE NAME: Functional Assessment of Chronic Illness Therapy - Satisfaction with Pharmacist (FACIT-SWiP) VERSION: 4 NUMBER OF ITEMS: 7 PATIENT POPULATION: Patients 18 and older receiving pharmacy care RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Satisfaction with Pharmacist Subscale TIME FOR COMPLETION: Less than 5 minutes SCORING: Manual scoring template, some items are reverse scored. Total scores possible. SAS/SPSS algorithms available. RELATED MEASURES: FACIT-TS-G , FACIT-TS-PS , CCSQ DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FACIT-SWiP can be obtained by registering for permission. Users are not permitted to translate the FACIT-SWiP without permission from FACIT.org. Permission from FACIT.org to translate the FACIT-SWiP may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Hernandez, L., Chang, C.H., Cella, D., Corona, M., Shiomoto, G., & McGuire, D.B. Development and validation of the Satisfaction with Pharmacist Scale. Pharmacotherapy 2000; 20(7): 837-843. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FACIT-TS-G Functional Assessment of Chronic Illness Therapy - Treatment Satisfaction – General LEARN MORE FACIT-TS-PS Functional Assessment of Chronic Illness Therapy - Treatment Satisfaction - Patient Satisfaction LEARN MORE CCSQ Chemotherapy Convenience and Satisfaction Questionnaire LEARN MORE

FKSI-15 Functional Assessment of Cancer Therapy Kidney Cancer Symptom Index - 15 Item Version For patients with Kidney Cancer, a 15 item scale LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview The FKSI-15 is a brief symptom index for assessing quality of life for advanced kidney cancer patients comprised of items from the FACIT Measurement System. It is composed of 15 items, nine of which assess disease-related symptoms specific to kidney cancer and six of which relate to other cancer patient concerns. MEASURE NAME: Functional Assessment of Cancer Therapy Kidney Cancer Symptom Index - 15 Item Version (FKSI-15) VERSION: 4 NUMBER OF ITEMS: 15 PATIENT POPULATION: Kidney cancer patients 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Kidney cancer symptom index TIME FOR COMPLETION: 5-10 minutes SCORING: Manual scoring template, some items are reverse scored. Total scores possible. SAS/SPSS algorithms available. RELATED MEASURES: NFKSI-19 , FKSI-DRS , FKSI-10 DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FKSI-15 can be obtained by registering for permission. Users are not permitted to translate the FKSI-15 without permission from FACIT.org. Permission from FACIT.org to translate the FKSI-15 may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Bukowski, R., Cella, D., Gondek, K., Escudier, B. Effects of sorafenib on symptoms and quality of life results from a large randomized placebo-controlled study in renal cancer. American Journal of Clinical Oncology; 2007: 30(3): 220-227. doi: 10.1097/01.coc.0000258732.80710.05. Butt, Z., Peipert, D., Webster, K., Chen, C., & Cella, D. General population norms for the functional assessment of cancer therapy – kidney symptom index (FKSI). Cancer 2013; 119(2): 429-437. doi: 10.1002/cncr.27688. Cella, D., Paul, D., Yount, S., Winn, R., Chang, C-H, Banik, D., & Weeks, J. What are the most important symptom targets when treating advanced cancer? A survey of providers in the National Comprehensive Cancer Network (NCCN). Cancer Investigation 2003; 21(4): 526-535. doi: 10.108/CNV-120022366. Cella, D., Yount, S., Brucker, P., Du, H., Bukowski, R., Vogelzang, N., Bro, W. Development and validation of a scale to measure disease-related symptoms of kidney cancer. Value in Health 2007; 10(4): 285-293. doi: 10.1111/j.1524-4733.2007.00183.x. Cella, D., Rosenbloom, S., Beaumont, J., Yount, J., Paul, D., Hampton, D., Abernethy, A., Jacobsen, P., Syrjala, K., & Von Roenn, J. Development and validation of 11 symptom indexes to evaluate response to chemotherapy for advanced cancer. Journal of the National Comprehensive Cancer Network; 2011; 9(3): 268-278. doi: 10.6004/jnccn.2011.0026. Cella, D., Escudier, B., Rini, B., Chen, C., Bhattacharyya, H., Tarzai, J., Rosbrook, B., Kim, S., & Motzer, R. Patient-reported outcomes for axitinib v sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial. British Journal of Cancer 2013; 108(8): 1571–1578. doi: 10.1038/bjc.2013. Luo, X., Cappelleri, J., Cella, D., Li, J., Charbonneau, C., Kim, S., Chen, I., & Motzer, R. Using the Rasch model to validate and enhance the interpretation of the functional assessment of cancer therapy-kidney symptom index-disease related symptoms scale. Value in Health 2009; 12(4): 580-586. doi: 10.1111/j.1524-4733.2008.00473.x. Motzer, R. , Hutson, T., Olsen, M., Hudes, G., Burke, J., Edenfield, W., Wilding, Agarwal, N., Thompson, J., Cella, D., Bello, A., Korytowksy, B., Yuan, J., Valota, O., Martell, B., Hariharan, S., & Figlin, R. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. Journal of Clinical Oncology 2012; 30(12): 1371-1377. doi: 10.1200/JCO.2011.36.4133. Rini, B., Wilding, G., Hudes, G., Stadler, W., Kim, S., Tarazi, J., Rosbrook, B., Trask, P., Wood, L., & Dutcher, J. Phase II Study of Axitinib in Sorafenib-Refractory Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology 2009; 27(27): 4462-4468. doi: 10.1200/JCO.2008.21.7034. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures NFKSI-19 National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Kidney Cancer Symptom Index - 19 Item Version LEARN MORE FKSI-DRS Functional Assessment of Cancer Therapy Kidney Cancer Symptom Index - Disease Related Symptoms LEARN MORE FKSI-10 Functional Assessment of Cancer Therapy Kidney Cancer Symptom Index - 10 Item Version LEARN MORE

View all available languages for this measure. BACK FACIT-TS-PS Languages Arabic English German Italian Romanian Serbian Spanish Swedish

FACT-HN-RAD Functional Assessment of Cancer Therapy – Head & Neck Radiotherapy Index For patients with Head & Neck cancer undergoing radiotherapy LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview The FACT-HN-RAD captures the most common patient- and physician-reported adverse events related to radiotherapy for patients with head and neck cancer, as well as providing a way to monitor patient-reported treatment-related adverse events and recovery over time in both clinical and research settings. MEASURE NAME: Functional Assessment of Cancer Therapy – Head & Neck Radiotherapy Index (FACT-HN-RAD) VERSION: 1 NUMBER OF ITEMS: 8 PATIENT POPULATION: Head & neck cancer patients 18 years and older undergoing radiotherapy treatment RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Radiotherapy index TIME FOR COMPLETION: Less than 5 minutes SCORING: Manual scoring template, some items are reverse scored. RELATED MEASURES: FHNSI , NFHNSI-22 , FACT-HN DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FACT-HN-RAD can be obtained by registering for permission. Users are not permitted to translate the FACT-HN-RAD without permission from FACIT.org. Permission from FACIT.org to translate the FACT-HN-RAD may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Gharzai LA, Mierzwa ML, Peipert JD, Kirtane K, Casper K, Yadav P, Rothrock N, Cella D, Shaunfield S. Monitoring Adverse Effects of Radiation Therapy in Patients With Head and Neck Cancer: The FACT-HN-RAD Patient-Reported Outcome Measure. JAMA Otolaryngol Head Neck Surg . 2023 Oct 1;149(10):884-890. doi: 10.1001/jamaoto.2023.2177. PMID: 37589994; PMCID: PMC10436187. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FHNSI Functional Assessment of Cancer Therapy Head & Neck Cancer Symptom Index - 10 Item Version LEARN MORE NFHNSI-22 National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Head & Neck Cancer Symptom Index - 22 Item Version LEARN MORE FACT-HN Functional Assessment of Cancer Therapy - Head & Neck LEARN MORE

Download scoring documents for this measure. BACK NFOSI-18 Scoring Downloads Download DOC

Download scoring documents for this measure. BACK PROMIS SF v1.0-Dyspnea-Severity 5a Scoring Downloads http://www.healthmeasures.net/score-and-interpret/calculate-scores/scoring-instructions